Wall Street analyst estimates for ADMA Biologics, Inc. (ADMA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.19 | ||
| 2026-08-05 | $0.16 | $0.16 | -2.0% |
| 2026-05-06 | $0.19 | $0.19 | -1.7% |
| 2026-02-25 | $0.20 | $0.18 | +8.1% |
| 2025-11-05 | $0.16 | $0.16 | +0.0% |
| 2025-08-06 | $0.15 | $0.14 | +7.1% |
| 2025-05-07 | $0.14 | $0.16 | -12.5% |
| 2025-03-03 | $0.14 | $0.15 | -6.7% |
Valuation Ratios
| P/E Ratio | 12.55 |
| Price / Book | 5.05 |
| EV / EBITDA | 21.93 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.7M | $22.8M | $17.0M | $29.3M | $42.2M | $80.9M | $154.1M | $258.2M | $426.5M | $510.2M |
| Cost of Revenue | $6.4M | $29.2M | $42.2M | $39.5M | $61.3M | $79.8M | $118.8M | $169.3M | $206.9M | $217.4M |
| Gross Profit | $4.3M | -$6.4M | -$25.2M | -$10.2M | -$19.1M | $1.2M | $35.3M | $88.9M | $219.6M | $292.8M |
| Research & Development | $7.7M | $6.2M | $3.9M | $2.3M | $5.9M | $3.6M | $3.6M | $3.3M | $1.8M | $4.8M |
| Selling, General & Admin | $8.5M | $18.1M | $22.5M | $25.9M | $35.1M | $42.9M | $52.5M | $59.0M | $74.1M | $91.6M |
| Operating Expenses | $21.6M | $32.1M | $35.1M | $31.3M | $45.8M | $59.5M | $74.6M | $67.3M | $80.6M | $101.3M |
| Operating Income | -$17.3M | -$39.3M | -$60.3M | -$41.4M | -$64.9M | -$58.4M | -$39.4M | $21.6M | $139.0M | $191.4M |
| EBITDA | -$16.8M | -$39.3M | -$56.8M | -$36.0M | -$59.8M | -$53.1M | -$39.5M | $5.1M | $147.7M | $197.9M |
| Interest Expense | $2.2M | $3.3M | $5.5M | $9.0M | $12.0M | $13.1M | $19.3M | $25.0M | $13.9M | $7.1M |
| Pre-tax Income | -$19.5M | -$43.8M | -$65.7M | -$48.3M | -$75.7M | -$71.6M | -$65.9M | -$28.2M | $125.7M | $182.7M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -$72.0M | $35.7M |
| Net Income | -$19.5M | -$43.8M | -$65.7M | -$48.3M | -$75.7M | -$71.6M | -$65.9M | -$28.2M | $197.7M | $146.9M |
| EPS | $-1.61 | $-1.91 | $-1.45 | $-1.05 | $-1.02 | $-0.61 | $-0.43 | $-0.13 | $0.85 | $0.62 |
| EPS (Diluted) | $-1.61 | $-1.91 | $-1.45 | $-1.05 | $-1.02 | $-0.61 | $-0.43 | $-0.13 | $0.81 | $0.60 |
| Shares Outstanding (Diluted) | $12.2M | $22.9M | $45.2M | $54.3M | $86.1M | $139.6M | $197.9M | $224.0M | $243.3M | $244.9M |
Price
| Price | $8.90 |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACAD · BLTE · CRNX · DYN · LGND · MIRM · PRAX
Explore sector: Healthcare · Biotechnology
More sections of ADMA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks